Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Bianchi

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Public Health Nutrition|July 9, 2026
The impact of restricting price promotions on foods high in fat, sugar, and salt on purchasing behaviours: A randomised controlled trial in a simulated online supermarketRu Jia, Filippo Bianchi, Madison Luick, et al.
Clinical Chemistry and Laboratory Medicine|January 27, 2023
Individual risk prediction of high grade prostate cancer based on the combination between total prostate-specific antigen (PSA) and free to total PSA ratioSimona Ferraro, Davide Biganzoli, Roberta Simona Rossi, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Public Health Nutrition|July 9, 2026
The impact of restricting price promotions on foods high in fat, sugar, and salt on purchasing behaviours: A randomised controlled trial in a simulated online supermarketRu Jia, Filippo Bianchi, Madison Luick, et al.
Clinical Chemistry and Laboratory Medicine|January 27, 2023
Individual risk prediction of high grade prostate cancer based on the combination between total prostate-specific antigen (PSA) and free to total PSA ratioSimona Ferraro, Davide Biganzoli, Roberta Simona Rossi, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Pageof 3